Middle East Healthcare (4009) Fundamentals 2026 — P/E 16.5x, Revenue Analysis | SniperIQ
Middle East Healthcare (4009) is a SA-listed Healthcare company in Medical - Care Facilities with a market capitalization of SAR 2.8B, trading at SAR 30.10 on the SAU. This SniperIQ fundamentals page covers Middle East Healthcare's valuation (P/E 16.5x, P/B 1.5x), profitability (net margin 5.3%), revenue (SAR 3.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Middle East Healthcare's market cap?
Middle East Healthcare (4009) has a market capitalization of approximately SAR 2.8B, trading at SAR 30.10 on the SAU. Market cap moves with the live share price.
What is Middle East Healthcare's P/E ratio?
Middle East Healthcare's trailing twelve-month P/E ratio is 16.5x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Middle East Healthcare?
Middle East Healthcare runs a net profit margin of 5.3%, a gross margin of 36.1%, and an operating margin of 11.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Middle East Healthcare generate?
Middle East Healthcare reported revenue of SAR 3.1B for fiscal year 2025, with net income of SAR 302M and earnings per share (EPS) of 3.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Middle East Healthcare pay a dividend?
Middle East Healthcare offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Middle East Healthcare financially healthy?
Middle East Healthcare carries a debt-to-equity ratio of 1.35x and a current ratio of 1.48x, with a market beta of -0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Middle East Healthcare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Middle East Healthcare (4009) the key facts are: market cap SAR 2.8B, P/E 16.5x, revenue SAR 3.1B, 52-week range 28.66-60.15. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Middle East Healthcare's full fundamentals live
Get Middle East Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.